Search results for "Serotonin reuptake"

showing 10 items of 61 documents

Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers.

1998

Paroxetine is a selective and potent serotonin reuptake inhibitor with reported antidepressant properties. Since changes in the regular sleeping pattern were described as side effects under treatment with paroxetine, the impact of the drug on the sleep architecture is of major interest. The present study addressed the question of subchronic effects of paroxetine medication (30 mg/day) in eight healthy male volunteers in a double blind, placebo-controlled crossover-design. Conventional sleep EEG parameters and additionally computed spectral power analysis based on FFT of 20-s time epochs in the delta, theta, alpha, beta and gamma frequency range for different sleep stages after 4 weeks of tr…

AdultMaleTime FactorsSerotonin reuptake inhibitorSleep REMNon-rapid eye movement sleepDouble-Blind MethodReference ValuesmedicineHumansPharmacology (medical)Biological PsychiatrySlow-wave sleepPharmacologySleep StagesAnalysis of VarianceCross-Over StudiesElectroencephalographySleep in non-human animalsParoxetineCircadian RhythmPsychiatry and Mental healthParoxetineNeurologyAnesthesiaAntidepressantAntidepressive Agents Second-GenerationNeurology (clinical)Sleep onset latencyPsychologySleepSelective Serotonin Reuptake Inhibitorsmedicine.drugEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers

2000

Abstract To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin w…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismSerotonin reuptake inhibitorPlaceboPlacebosMelatoninEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansBiological PsychiatryMelatoninCross-Over StudiesHuman Growth HormoneEndocrine and Autonomic SystemsElectroencephalographyLuteinizing HormoneParoxetineHormonesProlactinCircadian RhythmProlactinParoxetinePsychiatry and Mental healthEndocrinologySleep onsetReuptake inhibitorPsychologyLuteinizing hormoneSelective Serotonin Reuptake Inhibitorshormones hormone substitutes and hormone antagonistsmedicine.drugPsychoneuroendocrinology
researchProduct

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depressi…

2003

OBJECTIVE Current clinical knowledge holds that antidepressants have a delayed onset of efficacy. However, the delayed onset hypothesis has been questioned recently by survival analytical approaches. We aimed to test whether early improvement under antidepressant treatment is a clinically useful predictor of later stable response and remission. METHOD We analyzed data from a randomized double-blind controlled trial with mirtazapine and paroxetine in patients with major depression (DSM-IV). Improvement was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) score reduction of > or = 20%. Stable response was defined as > or = 50% HAM-D-17 score reduction at week 4 and week 6,…

AdultMalemedicine.medical_specialtyAdolescentMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatrySurvival analysisDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedPrognosisParoxetineSurvival AnalysisClinical trialPsychiatry and Mental healthParoxetineTreatment OutcomeAntidepressantDrug Therapy CombinationFemalePsychologySelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Compliance to therapy with Dapoxetine in patients affected by Premature Ejaculation

2012

Introduction Premature ejaculation (PE) is a sexual dysfunction with high prevalence. According to some reports, it is present in about 20-30% of the male population. Since 2009 PE has been treated with a novel inhibitor of serotonin re-uptake, Dapoxetine, which has been reported to be specifically active for PE. Materials and Methods 59 patients have been selected among the patients affected by PE observed at the outpatient department of Urology and Andrology of the “Paolo Giaccone” University Policlinic Hospital of Palermo. Diagnosis was confirmed unequivocally in all patients, who were suitable for drug treatment and accepted to participate in the study. They were divided in 2 groups: on…

AdultMalemedicine.medical_specialtyBenzylaminespremature ejaculation dapoxetine Cytalopram compliance side effectsAdolescentGastrointestinal DiseasesMigraine DisordersComorbidityCitalopramCitalopramNaphthalenesMedication AdherenceSettore MED/24 - UrologiaDrug treatmentYoung AdultInternal medicineSurveys and QuestionnairesPremature ejaculationmedicineOutpatient clinicHumansIn patientPremature EjaculationEiaculazione precoce dapoxetina citalopram compliance effetti collateraliLife StyleAgedGynecologyHigh prevalencebusiness.industryGeneral MedicineMiddle AgedPatient Acceptance of Health CareDapoxetineSexual dysfunctionmedicine.symptomNervous System DiseasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders.

2012

Whether responses to antidepressants differ in bipolar and unipolar depression remains unresolved.We analyzed patient characteristics and outcomes of antidepressant treatment of 1036 depressed patients with bipolar-I or bipolar-II disorder, or unipolar major depression, using bivariate and multivariate methods and survival analysis, testing the hypothesis that responses would be superior in unipolar depression.Antidepressants were given to 84.8% (878/1036) of depressed patients: 58.9% of 93 bipolar-I, 80.1% of 117 bipolar-II, and 91.3% of 668 unipolar disorder cases. The 158 not given antidepressants had more manias/year, spent more months in mania and depression, and were far more likely t…

AdultMalemedicine.medical_specialtyBipolar DisorderMonoamine Oxidase InhibitorsAntidepressive Agents Tricyclicbehavioral disciplines and activitiesInternal medicinemental disordersmedicineHumansBipolar disorderPsychiatrySurvival analysisDepression (differential diagnoses)Depressive Disorder MajorManic MoodMiddle Agedmedicine.diseaseAntidepressive AgentsPsychiatry and Mental healthMoodTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptomPsychologyManiaSelective Serotonin Reuptake InhibitorsActa psychiatrica Scandinavica
researchProduct

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

1998

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psych…

AdultMalemedicine.medical_specialtyPharmacologyPharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyClozapineBiological PsychiatryClozapinePharmacologymedicine.diseaseParoxetineClinical trialPsychiatry and Mental healthParoxetineNeurologyTolerabilitySchizophreniaConcomitantSchizophreniaDrug Therapy CombinationFemaleNeurology (clinical)PsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Pharmacological interventions for somatoform disorders in adults

2014

BACKGROUND: Somatoform disorders are characterised by chronic, medically unexplained physical symptoms (MUPS). Although different medications are part of treatment routines for people with somatoform disorders in clinics and private practices, there exists no systematic review or meta-analysis on the efficacy and tolerability of these medications. We aimed to synthesise to improve optimal treatment decisions.OBJECTIVES: To assess the effects of pharmacological interventions for somatoform disorders (specifically somatisation disorder, undifferentiated somatoform disorder, somatoform autonomic dysfunction, and pain disorder) in adults.SEARCH METHODS: We searched the Cochrane Depression, Anxi…

Adultmedicine.medical_specialtylow-quality evidencemedicine.medical_treatmentPsychiatry and PsychologyAntidepressive Agents TricyclicCochrane LibraryPlaceboInternal medicineMedicine and Health SciencesmedicineHumansPharmacology (medical)somatoform disorderSomatoform DisordersAntipsychoticPsychiatryinterventionRandomized Controlled Trials as TopicPain disorderMedically unexplained physical symptomsbusiness.industrytrialsMiddle Agedmedicine.diseaseClinical trialPsychological Phenomena and ProcessesTolerabilityMeta-analysisAntidepressive Agents Second-GenerationbusinessSelective Serotonin Reuptake InhibitorsAntipsychotic AgentsCochrane Database of Systematic Reviews
researchProduct

Characterisation of serotonin transport mechanisms in rainbow trout peripheral blood lymphocytes: role in PHA-induced lymphoproliferation

1999

Abstract AbstractIn this study we investigated the serotonin transport mechanisms in rainbow trout (Oncorhynchus mykiss) peripheral blood lymphocytes We have observed that the transport of serotonin is a membrane transport process that have the properties of a secondary active transport system The binding isotherm of [3H]-paroxetine a serotonin transport blocker demonstrated a high-affinity binding site with a positive type of cooperativity Hill coefficient being higher than unity Known specific inhibitors of the mammalian serotonin transporter significantly inhibited the uptake process in fish lymphocytes In order to demonstrate the physiological relevance of the serotonin transporter in T…

AgonistSerotoninmedicine.medical_specialtySerotonin uptakemedicine.drug_classImmunologySerotonin transportNerve Tissue ProteinsLymphocyte ActivationInternal medicineCyclic AMPmedicineAnimalsLymphocytesPhytohemagglutininsSerotonin Uptake InhibitorsSerotonin transporterSerotonin Plasma Membrane Transport ProteinsMembrane GlycoproteinsbiologyMembrane Transport ProteinsBiological TransportMembrane transportEndocrinologyOncorhynchus mykissActive transportbiology.proteinSerotoninCarrier ProteinsSelective Serotonin Reuptake InhibitorsDevelopmental BiologyDevelopmental & Comparative Immunology
researchProduct

GRANULOMATOUS MASTITIS DURING CHRONIC ANTIDEPRESSANT THERAPY: IS IT POSSIBLE A CONSERVATIVE THERAPEUTIC APPROACH?

2012

Granulomatous mastitis is a rare benign inflammatory disease of the breast with multiple etiologies such as tuberculosis, sarcoidosis, foreign body reaction, and mycotic and parasitic infections. In contrast, idiopathic granulomatous mastitis (IGM) is characterized by the presence of chronic granulomatous lobulitis in the absence of an obvious etiology. Clinically and radiologically it may mimic breast carcinoma and so awareness of surgeons, pathologists, and radiologists is essential to avoid unnecessary mastectomies. Cases of IGM are reported during antidepressant therapy in patients also showing high levels of prolactinemia. In these cases, we believe that surgical excision must be avoid…

Antidepressant therapyCancer Researchmedicine.medical_specialtyTuberculosisbusiness.industryDiseaseGranulomatous mastitismedicine.diseaseBrief CommunicationDermatologySurgeryHyperprolactinemiaTherapeutic approachSettore MED/18 - Chirurgia GeneraleBreast cancerOncologySelective serotonin reuptake inhibitorsmedicineEtiologySarcoidosisantidepressant therapy idiopathic granulomatous mastitis selective serotin reuptake inhibitorsIdiopathic granulomatous mastitisbusinessPathological
researchProduct

Pharmacokinetics of selective serotonin reuptake inhibitors

2000

The five selective serotonin reuptake inhibitors (SSRIs), fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, have similar antidepressant efficacy and a similar side effect profile. They differ, however, in their pharmacokinetic properties. Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs. Sertraline and citalopram show linear and fluoxetine, fluvoxamine, and paroxetine nonlinear pharmacokinetics. SSRIs underlie an extensive metabolism with high interindividual variability, whereby cytochrome P450 (CYP) isoenzymes play a major rol…

CYP2D6FluvoxamineCitalopramPharmacologyCitalopramSerotonergicbehavioral disciplines and activitiesFluoxetineSertralinemental disordersmedicineHumansDrug InteractionsPharmacology (medical)Serotonin Uptake InhibitorsPharmacologyClinical Trials as TopicFluoxetineSertralinebusiness.industryParoxetineParoxetineFluvoxaminebusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugPharmacology & Therapeutics
researchProduct